The outbreak related to severe acute respiratory syndrome (SARS-COV-2) was first detected and reported in Wuhan-china in December 2019 and declared as a pandemic by the world health organization (WHO) on March 11, 2020. Also commonly known simply as the coronavirus, it comes under the family Coronaviridae. The covid-19 epidemic has changed the global focus of health care and also created an unpredictable crisis in every aspect of the healthcare system all over the world. Patients with covid-19 were treated with board spectrum antibiotics with unknown efficacy because covid-19 patients frequently need to prolong hospitalization and respiratory support. The nature and rationale for antibiotics prescribing in patients suspected to covid 19 are not well established. The study investigates the role of Azithromycin therapy and its impact on prognosis along with the appropriateness of azithromycin and also usefulness and its benefits. Antibiotics have been used in hospitals empirically to treat patients with covid 19 due to overlapping clinical and radiological features of secondary bacterial respiratory tract infection. The macrolide antibiotic azithromycin has been one of the recommended therapy against covid-19. Azithromycin (500 mg 0.D, followed by 250 mg OD for 2-5 days) has great assess on lung tissue and wide range of antibacterial efficacy, Conceivable antiviral action against covid-19. The covid-19 patient can lead to a steep increase in antibiotics use during the era of pandemic and as a result a potential increase in antimicrobial resistance rate.

COVID-19, AZITHROMYCIN, ANTIBIOTICS, SECONDARY BACTERIAL INFECTION, ANTIVIRAL EFFECTS